-
Mashup Score: 4
Lisocabtagene maraleucel led to promising responses in relapsed/refractory marginal zone lymphoma, offering a new option with manageable safety.
Source: www.targetedonc.comCategories: General Medicine NewsTweet
Lisocabtagene maraleucel led to promising responses in relapsed/refractory marginal zone lymphoma, offering a new option with manageable safety.
The #MZL cohort of the TRANSCEND FL trial demonstrated high rates of durable responses with liso-cel in patients with relapsed/ refractory #MZL.@icmlugano #18ICML https://t.co/qVs6u9XouE